ISRCTN13466428 https://doi.org/10.1186/ISRCTN13466428

# The relationship between stomach Helicobacter pylori infection and antibiotic consumption among HIV-positive individuals

**Submission date**
30/09/2020

**Registration date**
03/10/2020

**Last Edited**
29/06/2021

**Recruitment status**
No longer recruiting

**Overall study status**
Completed

**Condition category**
Infections and Infestations

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

## Plain English summary of protocol

Background and study aims
Helicobacter pylori infection, a cause of ulcers and cancer in the stomach, and ulcers in the intestines is frequent worldwide and treatment is well established in the general population. H. pylori infects more than half of the world's population and HIV infects nearly thirty-eight million people. HIV-infected individuals often need treatments against infections. Compared to the general population, little is known about the H. pylori infection among HIV-co-infected individuals.
This study aimed to evaluate the presence of and evolution of primary antibiotic resistance of H. pylori strains isolated amongst HIV-co-infected (case) and -uninfected (control) individuals.

Who can participate?
Any adult aged 18 or more who have a proven H. pylori infection by microbiology examination including antimicrobial susceptibility test and have not yet been treated for H. pylori infection will be invited to participate in the study.

What does the study involve?
The study involves an agreement to use results of the microbiology examination and clinical data for the research.

What are the possible benefits and risks of participating?
There will be no direct benefit from taking part although it is hoped that participants might contribute to improve our understanding. Investigators do not anticipate any risks from taking part.

Where is the study run from?
University Hospital Saint Peter in Brussels (Belgium)

When is the study starting and how long is it expected to run for?
January 2004 to December 2023.

Who is funding the study?
Principal investigator with the support of FRPD ASBL

Who is the main contact?
Dr Marcel Nkuize, marcel.nkuize@stpierre-bru.be

# Contact information

### Type(s)
Scientific

### Contact name
Dr Marcel Nkuize

### ORCID ID
https://orcid.org/0000-0002-7708-050X

### Contact details
Centre Hospitalier Universitaire de Saint-Pierre
322 Rue Haute
Brussels
Belgium
1000
+32 25354200
marcelnkuize@hotmail.com

### Type(s)
Scientific

### Contact name
Dr Marcel Nkuize

### ORCID ID
https://orcid.org/0000-0002-7708-050X

### Contact details
Centre Hospitalier Universitaire de Saint-Pierre
322 Rue Haute
Brussels
Belgium
1000
+32 25354200
marcel.nkuize@stpierre-bru.be

# Additional identifiers

### Clinical Trials Information System (CTIS)
Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number
AK/07-12-77/3503

# Study information

### Scientific Title
Evolution of Helicobacter pylori primary antibiotic resistance in a cohort of individuals with and without HIV infection: role of antibiotics consumption

### Acronym
HPPARHIV

### Study objectives
To evaluate prevalence and evolution of primary antibiotic resistance of Helicobacter pylori (H. pylori) strains isolated amongst HIV-co-infected (case) and -uninfected (control) individuals.
To correlate local patient’s antibiotic resistance of H. pylori strains with nationwide antibiotic consumption.

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Approved 04/12/2007, Comite Local d'Ethique Hospitalier (Rue Haute 322-1000 Brussels, Belgium; +3225354481; comite_ethique@stpierre-bru.bee), ref: AK/07-12-77/3503

### Study design
Observational

### Primary study design
Observational

### Study type(s)
Diagnostic

### Health condition(s) or problem(s) studied
Helicobacter pylori antimicrobial susceptibility in people with HIV infection

### Interventions
Participants who fulfil inclusion criteria will be asked to give consent for the team to collect clinical information, as well as data related to H. pylori diagnosis.

We prospectively collected in a registry, data of local outpatients, from 1st of January, 2004 till 31st of December, 2015.
We collected Nationwide outpatient (with and without HIV infection) antibiotic consumption during the same period since 1st of January, 2004 till 31st of December, 2015.

### Intervention Type
Mixed

### Primary outcome(s)
1. Primary H. pylori antibiotic resistance is evaluated by anamnesis and by microbial examination of gastric samples using disk diffusion methods (Neo-Sensitabs; Rosco, Taastrup, Denmark), and the minimum inhibitory concentration (MIC) determined by an agar dilution method at a single time point
2. Antibiotic consumption within the country during the period studied, measured by defined daily dose per 1000 inhabitants using national records

### Key secondary outcome(s))
Measured at the time of H. pylori diagnosis:
1. Demographics measured using anamnesis, medical records, and hospital database
2. History of H. pylori treatment obtained by anamnesis, patient's medical chart, phone contact with the family medical doctor
3. HIV status measured using medical records
4. HIV viral load (measured using COBAS AmpliPrep/COBAS Amplicor HIV-1 Monitor Test v1.0, 1COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 real time PCR)
5. Lymphocyte T CD4 count (measured using flow cytometry, NAVIOS)
6. Chemoprevention against Toxoplasma gondii or Pneumocystis jiroveci ( with trimethoprim-sulfamethoxazole ) or anti-malaria drug use (including mefloquine, atovaquone, chloroquine, primaquine)
7. Consequences of infection measured by endoscopy performed using video Olympus GIF-q165, GIF-HQ 190 and gastric biopsy

### Completion date
31/12/2023

## Eligibility

### Key inclusion criteria
1. No history of H. pylori treatment
2. Ambulatory HIV-positive and HIV-negative individuals
3. Naïve to H. pylori treatment
4. Aged ≥18 years
5. Underwent upper gastrointestinal endoscopy for any reason and for which H. pylori antimicrobial susceptibility test results is available

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Adult

### Lower age limit
18 years

### Sex
All

### Total final enrolment
8321

### Key exclusion criteria
1. Coagulopathy
2. Partial gastrectomy
3. Does not agree to participate

### Date of first enrolment
01/01/2006

### Date of final enrolment
31/12/2015

## Locations

### Countries of recruitment
Belgium

### Study participating centre
**University Hospital Saint Peter**
322 Rue Haute
Brussels
Belgium
1000

## Sponsor information

### Organisation
Centre Hospitalier Universitaire de Saint-Pierre

### ROR
https://ror.org/05cmp5q80

## Funder(s)

### Funder type
Not defined

### Funder Name
Principal Investigator

**Funder Name**
Fond de recherche en pathologie digestive, FRDP ASBL

# Results and Publications

## Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

## IPD sharing plan summary
Available on request

## Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | | 01/06/2021 | 29/06/2021 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |